Cyclacel Pharmaceuticals ... (CYCC)
Cyclacel Pharmaceuticals Statistics
Share Statistics
Cyclacel Pharmaceuticals has 11.26M shares outstanding. The number of shares has increased by 376.93% in one year.
| Shares Outstanding | 11.26M |
| Shares Change (YoY) | 376.93% |
| Shares Change (QoQ) | 218.47% |
| Owned by Institutions (%) | 9.04% |
| Shares Floating | 8.5M |
| Failed to Deliver (FTD) Shares | 1.33K |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 66.77K, so 0.59% of the outstanding shares have been sold short.
| Short Interest | 66.77K |
| Short % of Shares Out | 0.59% |
| Short % of Float | 0.61% |
| Short Ratio (days to cover) | 0.03 |
Valuation Ratios
The PE ratio is -0.1 and the forward PE ratio is -0.18. Cyclacel Pharmaceuticals's PEG ratio is 0.01.
| PE Ratio | -0.1 |
| Forward PE | -0.18 |
| PS Ratio | 5.41 |
| Forward PS | 0 |
| PB Ratio | 3.74 |
| P/FCF Ratio | -0.14 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Cyclacel Pharmaceuticals Inc. has an Enterprise Value (EV) of -1.07M.
| EV / Earnings | 0.05 |
| EV / Sales | -2.55 |
| EV / EBITDA | 0.04 |
| EV / EBIT | 0.04 |
| EV / FCF | 0.07 |
Financial Position
The company has a current ratio of 0.91, with a Debt / Equity ratio of 0.06.
| Current Ratio | 0.91 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.06 |
| Total Debt / Capitalization | 5.75 |
| Cash Flow / Debt | -435.46 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -37.16% and return on capital (ROIC) is -3488.9%.
| Return on Equity (ROE) | -37.16% |
| Return on Assets (ROA) | -2.56% |
| Return on Capital (ROIC) | -3488.9% |
| Revenue Per Employee | 35K |
| Profits Per Employee | -1.88M |
| Employee Count | 12 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3M |
| Effective Tax Rate | 0.12 |
Stock Price Statistics
The stock price has increased by -88.62% in the last 52 weeks. The beta is 0.35, so Cyclacel Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.35 |
| 52-Week Price Change | -88.62% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 1.01 |
| Relative Strength Index (RSI) | 46.54 |
| Average Volume (20 Days) | 2.44M |
Income Statement
In the last 12 months, Cyclacel Pharmaceuticals had revenue of 420K and earned -22.55M in profits. Earnings per share was -26.75.
| Revenue | 420K |
| Gross Profit | 420K |
| Operating Income | -25.45M |
| Net Income | -22.55M |
| EBITDA | -25.42M |
| EBIT | -25.45M |
| Earnings Per Share (EPS) | -26.75 |
Balance Sheet
The company has 3.38M in cash and 37K in debt, giving a net cash position of 3.34M.
| Cash & Cash Equivalents | 3.38M |
| Total Debt | 37K |
| Net Cash | 3.34M |
| Retained Earnings | -428.28M |
| Total Assets | 5.38M |
| Working Capital | -6.35M |
Cash Flow
In the last 12 months, operating cash flow was -16.11M and capital expenditures -6K, giving a free cash flow of -16.12M.
| Operating Cash Flow | -16.11M |
| Capital Expenditures | -6K |
| Free Cash Flow | -16.12M |
| FCF Per Share | -18.94 |
Margins
Gross margin is 100%, with operating and profit margins of -6.06K% and -5.37K%.
| Gross Margin | 100% |
| Operating Margin | -6.06K% |
| Pretax Margin | -6.08K% |
| Profit Margin | -5.37K% |
| EBITDA Margin | -6.05K% |
| EBIT Margin | -6.06K% |
| FCF Margin | -3.84K% |
Dividends & Yields
CYCC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8106.06% |
| FCF Yield | -435.5% |
Analyst Forecast
The average price target for CYCC is $11, which is 3233.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 3233.3% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 18, 2023. It was a backward split with a ratio of 1:15.
| Last Split Date | Dec 18, 2023 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -124.14 |
| Piotroski F-Score | 2 |